# Resolving Bivalirudin Interference on Fibrinogen Testing by the Use of Activated Carbon

**Authors:** Jia Du, Haiyan Liu, Xiaohui Liu, Shuzheng Cao, Zhenlu Zhang, Litao Zhang

PMC · DOI: 10.1002/jcla.70184 · Journal of Clinical Laboratory Analysis · 2026-02-18

## TL;DR

Bivalirudin can cause falsely low fibrinogen test results, but adding activated carbon can eliminate this interference.

## Contribution

Demonstrates that activated carbon can effectively remove bivalirudin interference in fibrinogen testing.

## Key findings

- Bivalirudin significantly lowers fibrinogen results in Clauss-method assays but not in immunoassays.
- Activated carbon restores fibrinogen levels to near baseline in bivalirudin-spiked plasma.
- The effect of bivalirudin on fibrinogen testing varies across different assay types.

## Abstract

Direct thrombin inhibitors may lead to falsely low fibrinogen results. The interference of bivalirudin on fibrinogen assays has not been thoroughly evaluated. This study investigates the interference of bivalirudin on fibrinogen detection and the potential use of activated carbon to address this issue.

Normal pooled plasma from 20 healthy subjects was spiked with increasing bivalirudin concentrations (0–6.4 μg/mL). Interference of bivalirudin on fibrinogen testing was evaluated by comparing three Clauss‐method assays (HemosIL Fibrinogen‐C XL; STA‐Fibrinogen; Dade Thrombin) to an immunoassay (N Antiserum to Human Fibrinogen reagent, NAHF). Activated partial thromboplastin time (APTT) and fibrinogen results were analyzed before and after the addition of activated carbon (AC) to evaluate the absorption of bivalirudin by AC.

The NAHF immunoassay remained unaffected by bivalirudin (p = 0.27). All three Clauss‐methods assays showed a significant downward trend with the increase of bivalirudin concentration (STA‐Fibrinogen: p = 0.012, Dade Thrombin: p < 0.001, Fibrinogen‐C XL: p < 0.001). When compared to their respective baselines, STA‐Fibrinogen exhibited a reduction of 16%, Dade Thrombin showed a reduction of 40%, and Fibrinogen‐C XL displayed a decrease of up to 89%. Neither STA‐Fibrinogen nor Dade Thrombin displayed a significant downward trend when the APTT ratio did not exceed 2.5. After the addition of AC, SynthASil APTT and HemosIL Fibrinogen‐C XL levels of all samples containing varying concentrations of bivalirudin returned to near baseline.

The influences of bivalirudin on fibrinogen assays vary significantly. Activated carbon can effectively remove bivalirudin from plasma, thereby eliminating its interference on fibrinogen testing.

The influences of bivalirudin on fibrinogen assays differ considerably. Activated carbon can effectively remove bivalirudin from plasma, thereby eliminating its interference in fibrinogen detection.

## Linked entities

- **Proteins:** FGB (fibrinogen beta chain)
- **Chemicals:** bivalirudin (PubChem CID 16129704), activated carbon (PubChem CID 5462310)

## Full-text entities

- **Genes:** GCY (growth control, Y chromosome influenced) [NCBI Gene 2656] {aka STA, TS, TSY}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}
- **Chemicals:** Activated Carbon (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13042697/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13042697/full.md

## References

16 references — full list in the complete paper: https://tomesphere.com/paper/PMC13042697/full.md

---
Source: https://tomesphere.com/paper/PMC13042697